Skip to content or view mobile version

Home | Mobile | Editorial | Mission | Privacy | About | Contact | Help | Security | Support

A network of individuals, independent and alternative media activists and organisations, offering grassroots, non-corporate, non-commercial coverage of important social and political issues.

Hidden Article

This posting has been hidden because it breaches the Indymedia UK (IMC UK) Editorial Guidelines.

IMC UK is an interactive site offering inclusive participation. All postings to the open publishing newswire are the responsibility of the individual authors and not of IMC UK. Although IMC UK volunteers attempt to ensure accuracy of the newswire, they take no responsibility legal or otherwise for the contents of the open publishing site. Mention of external web sites or services is for information purposes only and constitutes neither an endorsement nor a recommendation.

PennyPerformers.com: Penny Stocks that OutPerform the Competition ---Tuesday, Ju

Mr Roger K. Olsson | 22.07.2007 22:41 | Analysis | Other Press | London | World

Giuen Media



Tuesday, July 17, 2007


Jul. 17, 2007 (M2 Communications Ltd. delivered by Newstex) --

PennyPerformers.coms 'Penny Stocks that Perform' for today are: Itronics Inc. (OTCBB: ITRO), Stem Cell Therapy International, Inc. (OTCBB: SCII), Tradequest International (OTCBB:TRDQ), Protein Polymer Technologies, Inc. (OTCBB: PPTI), Calypte Biomedical Corporation (OTCBB: CBMC), Modigene Inc. (OTCBB: MODG)

Sign-up for our FREE Stock Alerts at  http://www.PennyPerformers.com and click here for our full Disclaimer at  http://www.PennyPerformers.com/disclaimer.htm

_____________________________________________________________________________________

Itronics Inc.

(OTCBB: ITRO)  http://www.PennyPerformers.com Itronics Inc. announced today that its wholly-owned subsidiary, Itronics Metallurgical, Inc. has completed the first milestone which entailed the completion of a draft label. It is working on the second milestone in the process of registering its new GOLD'n GRO GUARDIAN(TM) liquid deer repellent fertilizer with the U.S. Environmental Protection Agency(EPA). Samples to be used for testing have been prepared and submitted to a testing laboratory to perform the required tests under the supervision of the Company's consultants. The testing is expected to be completed within 90 to 120 days.

The Company now believes that it is on schedule to complete the entire registration process late in the first quarter or early in the second quarter of 2008. The Company is developing plans for manufacturing and marketing GOLD'n GRO GUARDIAN(TM), and is targeting a sales launch in the second quarter 2008.

'In parallel with the registration process, the Company has reached agreement to enter into a long term supply arrangement with a large foreign manufacturer of the repelling ingredient,' said Dr. John Whitney, Itronics President. 'Having an agreement for reliable supply of a critical ingredient, which is not manufactured within the United States, should make it easier to ramp up manufacturing and sales once the registration process is completed.' The GOLD'n GRO GUARDIAN(TM) repels deer without harming them while it also improves the growth of the fertilized plants. The treatment is systemic, which means that the repelling characteristics are taken into the plant and do not wash off when it rains. Field tests have shown that plants treated in the fall will retain their repelling characteristics during the winter, a major benefit.

The national annual market for deer repellent products is growing rapidly and is estimated to exceed $50 million. Deer damage in the United States is a large and growing problem. According to a report by Cornell Cooperative Extension, Ithaca, N.Y., the deer population has grown from 500,000 nationwide in the early 1900's to more than 15 million today. Annual estimates of deer damage are reported to exceed $2 billion nationwide, including more than $100 million in agricultural crop damage, and more than $250 million in damage to metropolitan households, including landscape plantings. The company has not identified any significant competition to its GOLD'n GRO GUARDIAN(TM) to combat the growing problem associated with deer damage.

For more information about Itronics Inc. visit:  http://www.itronics.com

Signup at  http://www.PennyPerformers.com for our newsletter, its free! ________________________________________________________________________

Stem Cell Therapy International, Inc.

(OTCBB: SCII)  http://www.PennyPerformers.com Stem Cell Therapy International, Inc. announced today that as reported in its 10KSB filing for the reporting period ending March 31, 2007 that it has increased revenues by 327% from its expanding stem cell treatment services over the comparable period in 2006. Calvin Cao, CEO of SCII.OB, went on to state, 'Not only have we been able to increase revenues, but we have eliminated a significant cost of goods that will now save the company $120,000 per year over what had been paid in the past. We are very encouraged by our progress so far and look forward to exploring the numerous opportunities we have available for continued growth and expansion.'

For more information about Stem Cell Therapy International, Inc. visit:  http://www.scticorp.com

Signup at  http://www.PennyPerformers.com for our newsletter, its free! ________________________________________________________________________

Tradequest International (OTCBB:TRDQ)  http://www.PennyPerformers.com Tradequest International, doing business as IP1 Network Corp., announced yesterday that it has signed a Preferred Partner Agreement with Dynamic Call, Inc. to market IP1 Network's complete line of Internet Protocol (IP) telephony networks and value-added Enhanced IP services to residential business customers and government clients located throughout Central America, with a concentration in Nicaragua, El Salvador, Honduras and Guatemala.

'We are excited to add Dynamic Call as one of our first Preferred Partner in the Central America market,' said Frank Erbiti, IP1 Network's President. 'We understand that one of the keys to success in securing end-users in the Central American marketplaces lies in building strong relationships and strategic channel partners throughout the region and Dynamic Call represents a significant existing customer base that will be immediately migrating from standard telephony service to IP based communications. We look forward to working with the employees of Dynamic Call in making our products and services available to their network of customers and internal call centers.' By utilizing IP1 Network's multi-level agent tools, Dynamic Call is expected to target market IP services in the US domestic markets comprising of Nicaraguan, Salvadoran, Honduran and Guatemalan communities. 'Dynamic's reputation within these communities makes them an ideal partner in capturing customers originating from the US that are seeking to communicate with friends, family, and businesses back home,' concluded Mr. Erbiti.

For more information about Tradequest International visit:  http://www.ip1network.com

Signup at  http://www.PennyPerformers.com for our newsletter, its free! ________________________________________________________________________

Protein Polymer Technologies, Inc.

(OTCBB: PPTI)  http://www.PennyPerformers.com Protein Polymer Technologies, Inc., a biotechnology device company that is a pioneer in protein design and synthesis, announced yesterday that they have entered into an agreement with a multinational biotechnology device company. According to the agreement, PPTI will provide genetically engineered protein polymer biomaterials for use in the prevention of post-surgical adhesions. 'This agreement further demonstrates our core competency; developing novel protein polymer biomaterials for challenging medical applications such as the prevention of surgical adhesions,' said William N. Plamondon, Chief Executive Officer of PPTI. 'Additionally, it furthers the progression of our plan to establish relationships with partners that will ultimately market the products. This relationship adds to the six others we have in product development which includes our license agreements with Spine Wave, Inc. and Genencor International, Inc.' Post-operative adhesions, unintended attachments between distinct tissues and organs in the body, occur after most surgical procedures. Most notable are the complications that arise from adhesions after abdominal and gynecological surgery. Studies have shown that between 55% and 100% of patients developed adhesions within six months of surgery. In severe cases, adhesions can cause pain, obstructions and infertility. More than 300,000 Americans are hospitalized each year at a cost of $1.3 billion to undergo surgery to remove adhesions. PPTI believes its protein polymer materials can improve the outcome of abdominal and gynecological surgery by substantially reducing adhesions.

PPTI is also in discussions with several U.S. and international biotechnology and medical device companies, which are evaluating PPTI's surgical sealant and drug delivery product applications. These products are intended to aid in the closure of surgical incisions and tissue trauma reducing, for example, the incidence of post-operative bleeding and the delivery locally of therapeutic agents. 'We have been successful here because of the competencies we've developed in manufacturing products, supporting clinical trials, and engineering application and delivery systems that support the biomaterials platform that we own,' said Joe Cappello, Chief Technology Officer of PPTI.

For more information about Protein Polymer Technologies, Inc. visit:  http://www.ppti.com

Signup at  http://www.PennyPerformers.com for our newsletter, its free! ________________________________________________________________________

Calypte Biomedical Corporation (OTCBB: CBMC)  http://www.PennyPerformers.com Calypte Biomedical Corporation, medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV) announced yesterday that Roger I. Gale, Chairman and Chief Executive Officer and Richard D. Brounstein, Executive Vice President, will speak to the investment community at CapStone Investments' First Annual Small-Cap Investor Conference in Milwaukee, Wisconsin. The conference will be archived for on-demand webcasting after the conference has concluded.

Mr. Gale and Mr. Brounstein will provide an update regarding the Company's recent activities at CapStone Investments' First Annual Small-Cap Investor Conference in Milwaukee, Wisconsin at approximately 2:30pm CDT on Tuesday, July 17, 2007.

For more information about Calypte Biomedical Corporation visit:  http://www.calypte.com

Signup at  http://www.PennyPerformers.com for our newsletter, its free!

________________________________________________________________________

Modigene Inc.

(OTCBB: MODG)  http://www.PennyPerformers.com Modigene Inc. announced yesterday that it has signed a contract with Xcellerex, Inc., to provide GMP production of hGH-CTP, Modigene's long-acting human growth hormone (hGH), for upcoming preclinical studies and for the Phase I clinical trials projected to begin next year.

'We are pleased to be working with Xcellerex, a high quality contract bio- manufacturer, as we prepare for clinical trials of our lead hGH-CTP product that are targeted for next year,' said Shai Novik, President of Modigene. 'Human growth hormone was one of the earliest biotech drugs and remains among the most important for children, but it can require frequent injections. In preclinical studies, our long-acting hGH-CTP has demonstrated its potential to significantly decrease the frequency of these injections, which could provide important benefits for patients. We look forward to having the GMP material on hand to advance hGH-CTP toward clinical trials.' Human growth hormone is a natural protein produced by the pituitary gland in the brain. hGH fuels growth of the body's bone and muscle and has a variety of therapeutic uses. In patients with an hGH deficiency, current treatments involve subcutaneous hGH injections on a near-daily basis. Approximately 95% of children diagnosed with a growth hormone deficiency currently receive treatment, with costs ranging from $10,000 to $30,000 per year. In preclinical models, a single injection of hGH-CTP has shown the potential to replace 7 to 10 daily injections of commercial hGH.

Modigene's technology is based on a short amino acid sequence, the Carboxyl Terminal Peptide (CTP). CTP occurs naturally in humans, and when attached to a therapeutic protein, extends the time that the protein is active in the body. The potential utility of the technology has been demonstrated by Organon, a unit of Akzo Nobel NV, which licenses the CTP technology for fertility applications only. Phase II trials of its CTP follicle stimulating hormone product (FSH-CTP) demonstrated that a single injection provides the same clinical effect as seven consecutive daily injections of standard FSH. These trials also demonstrated that attaching the CTP peptide did not affect the therapeutic activity of FSH or cause a negative immune system response. Modigene has an exclusive license from Washington University for use of CTP with all therapeutic proteins except fertility hormones. Modigene currently has four CTP-enhanced compounds in preclinical development and is preparing to initiate clinical trials in 2008.

Under the terms of the agreement, Xcellerex will produce enough hGH-CTP for further preclinical studies as well as for Phase I and Phase II clinical trials.

For more information about Modigene Inc. visit:  http://www.modigenetech.com

Signup at  http://www.PennyPerformers.com for our newsletter, its free!

________________________________________________________________________

About PennyPerformers.com

PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the 'join now' button.

Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains 'forward looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be 'forward looking statements'. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm

(Comments on this story may be sent to  tww.feedback@m2.com)


Newstex ID: MCOM-0001-18191502


Delivered by Newstex LLC
via theFinancials.com

Mr Roger K. Olsson
- e-mail: rogerkolsson@yahoo.co.uk
- Homepage: http://giuen.wordpress.com

Upcoming Coverage
View and post events
Upcoming Events UK
24th October, London: 2015 London Anarchist Bookfair
2nd - 8th November: Wrexham, Wales, UK & Everywhere: Week of Action Against the North Wales Prison & the Prison Industrial Complex. Cymraeg: Wythnos o Weithredu yn Erbyn Carchar Gogledd Cymru

Ongoing UK
Every Tuesday 6pm-8pm, Yorkshire: Demo/vigil at NSA/NRO Menwith Hill US Spy Base More info: CAAB.

Every Tuesday, UK & worldwide: Counter Terror Tuesdays. Call the US Embassy nearest to you to protest Obama's Terror Tuesdays. More info here

Every day, London: Vigil for Julian Assange outside Ecuadorian Embassy

Parliament Sq Protest: see topic page
Ongoing Global
Rossport, Ireland: see topic page
Israel-Palestine: Israel Indymedia | Palestine Indymedia
Oaxaca: Chiapas Indymedia
Regions
All Regions
Birmingham
Cambridge
Liverpool
London
Oxford
Sheffield
South Coast
Wales
World
Other Local IMCs
Bristol/South West
Nottingham
Scotland
Social Media
You can follow @ukindymedia on indy.im and Twitter. We are working on a Twitter policy. We do not use Facebook, and advise you not to either.
Support Us
We need help paying the bills for hosting this site, please consider supporting us financially.
Other Media Projects
Schnews
Dissident Island Radio
Corporate Watch
Media Lens
VisionOnTV
Earth First! Action Update
Earth First! Action Reports
Topics
All Topics
Afghanistan
Analysis
Animal Liberation
Anti-Nuclear
Anti-militarism
Anti-racism
Bio-technology
Climate Chaos
Culture
Ecology
Education
Energy Crisis
Fracking
Free Spaces
Gender
Globalisation
Health
History
Indymedia
Iraq
Migration
Ocean Defence
Other Press
Palestine
Policing
Public sector cuts
Repression
Social Struggles
Technology
Terror War
Workers' Movements
Zapatista
Major Reports
NATO 2014
G8 2013
Workfare
2011 Census Resistance
Occupy Everywhere
August Riots
Dale Farm
J30 Strike
Flotilla to Gaza
Mayday 2010
Tar Sands
G20 London Summit
University Occupations for Gaza
Guantanamo
Indymedia Server Seizure
COP15 Climate Summit 2009
Carmel Agrexco
G8 Japan 2008
SHAC
Stop Sequani
Stop RWB
Climate Camp 2008
Oaxaca Uprising
Rossport Solidarity
Smash EDO
SOCPA
Past Major Reports
Encrypted Page
You are viewing this page using an encrypted connection. If you bookmark this page or send its address in an email you might want to use the un-encrypted address of this page.
If you recieved a warning about an untrusted root certificate please install the CAcert root certificate, for more information see the security page.

Global IMC Network


www.indymedia.org

Projects
print
radio
satellite tv
video

Africa

Europe
antwerpen
armenia
athens
austria
barcelona
belarus
belgium
belgrade
brussels
bulgaria
calabria
croatia
cyprus
emilia-romagna
estrecho / madiaq
galiza
germany
grenoble
hungary
ireland
istanbul
italy
la plana
liege
liguria
lille
linksunten
lombardia
madrid
malta
marseille
nantes
napoli
netherlands
northern england
nottingham imc
paris/île-de-france
patras
piemonte
poland
portugal
roma
romania
russia
sardegna
scotland
sverige
switzerland
torun
toscana
ukraine
united kingdom
valencia

Latin America
argentina
bolivia
chiapas
chile
chile sur
cmi brasil
cmi sucre
colombia
ecuador
mexico
peru
puerto rico
qollasuyu
rosario
santiago
tijuana
uruguay
valparaiso
venezuela

Oceania
aotearoa
brisbane
burma
darwin
jakarta
manila
melbourne
perth
qc
sydney

South Asia
india


United States
arizona
arkansas
asheville
atlanta
Austin
binghamton
boston
buffalo
chicago
cleveland
colorado
columbus
dc
hawaii
houston
hudson mohawk
kansas city
la
madison
maine
miami
michigan
milwaukee
minneapolis/st. paul
new hampshire
new jersey
new mexico
new orleans
north carolina
north texas
nyc
oklahoma
philadelphia
pittsburgh
portland
richmond
rochester
rogue valley
saint louis
san diego
san francisco
san francisco bay area
santa barbara
santa cruz, ca
sarasota
seattle
tampa bay
united states
urbana-champaign
vermont
western mass
worcester

West Asia
Armenia
Beirut
Israel
Palestine

Topics
biotech

Process
fbi/legal updates
mailing lists
process & imc docs
tech